EA
ANIK icon

Emerald Acquisition’s Anika Therapeutics ANIK Stock Holding History

Emerald Acquisition’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$4.7M Sell
98,306
-23,618
-19% -$1.17M 0.01% 1246
2016
Q2 		$6.54M Buy
+121,924
New +$5.74M 0.01% 1174

Other funds holding ANIK

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

Emerald Acquisition's ANIK Position: Q3 2016 in Review

Emerald Acquisition reduced its Anika Therapeutics (ANIK) stake by 19% in Q3 2016, selling an estimated $1.17M and leaving 98,306 shares worth $4.7M. The position accounts for 0.01% of the portfolio, ranked #1246.

Emerald Acquisition first reported a position in ANIK in Q2 2016 and has held it in 2 quarters since. The position peaked at $6.54M in Q2 2016. 163 funds tracked by Wall St. Rank hold ANIK as of Q3 2016.

  • Emerald Acquisition held 98,306 shares of Anika Therapeutics worth $4.7M as of Q3 2016.
  • Emerald Acquisition sold 23,618 Anika Therapeutics shares in Q3 2016, an estimated $1.17M.
  • Anika Therapeutics made up 0.01% of Emerald Acquisition's portfolio in Q3 2016, its #1246 holding.
  • Emerald Acquisition first reported a position in Anika Therapeutics in Q2 2016 and has held it in 2 quarters since.
  • Emerald Acquisition's Anika Therapeutics position peaked at $6.54M in Q2 2016.
  • 163 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.